KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Recursion Pharmaceuticals (RXRX) EPS (Basic): 2020-2025

Historic EPS (Basic) for Recursion Pharmaceuticals (RXRX) over the last 6 years, with Sep 2025 value amounting to -$0.36.

  • Recursion Pharmaceuticals' EPS (Basic) fell 5.88% to -$0.36 in Q3 2025 from the same period last year, while for Sep 2025 it was -$1.84, marking a year-over-year decrease of 18.71%. This contributed to the annual value of -$1.69 for FY2024, which is 6.96% down from last year.
  • Per Recursion Pharmaceuticals' latest filing, its EPS (Basic) stood at -$0.36 for Q3 2025, which was up 12.20% from -$0.41 recorded in Q2 2025.
  • Recursion Pharmaceuticals' 5-year EPS (Basic) high stood at -$0.28 for Q3 2021, and its period low was -$1.33 during Q1 2021.
  • In the last 3 years, Recursion Pharmaceuticals' EPS (Basic) had a median value of -$0.40 in 2024 and averaged -$0.41.
  • Per our database at Business Quant, Recursion Pharmaceuticals' EPS (Basic) tumbled by 56.47% in 2021 and then soared by 75.19% in 2022.
  • Recursion Pharmaceuticals' EPS (Basic) (Quarterly) stood at -$0.39 in 2021, then increased by 23.08% to -$0.30 in 2022, then plummeted by 40.00% to -$0.42 in 2023, then crashed by 35.71% to -$0.57 in 2024, then fell by 5.88% to -$0.36 in 2025.
  • Its EPS (Basic) was -$0.36 in Q3 2025, compared to -$0.41 in Q2 2025 and -$0.50 in Q1 2025.